Skip to main content
. 2011 Jan 17;22(5):1041–1047. doi: 10.1093/annonc/mdq564

Figure 1.

Figure 1.

Progression-free survival curves. Some patients were not included: (A) rapid PD/death (n = 2). Patients changed to sorafenib (n = 1). (B) Bone metastasis only (n = 3) rapid PD/death (n = 3). Patients changed to sorafenib (n = 1).